Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development

Dorothy I. Shulman, Gary L. Francis, Mark R. Palmert, Erica Eugster

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Although treatment of children and adolescents who have disorders of growth and adolescent development with aromatase inhibitors is increasingly common, data for or against their use are extremely limited. Precocious puberty, short stature, and gynecomastia are conditions for which inhibition of the enzyme aromatase might prove beneficial to reduce clinical signs of estrogenization and/or estrogen-mediated skeletal maturation. In this report, we summarize the published data regarding the use of aromatase inhibitors in these conditions, and review known and potential benefits, safety concerns, and shortcomings of the available information.

Original languageEnglish
JournalPediatrics
Volume121
Issue number4
DOIs
StatePublished - Apr 2008

Fingerprint

Adolescent Development
Aromatase Inhibitors
Growth and Development
Gynecomastia
Precocious Puberty
Aromatase
Estrogens
Safety
Enzymes
Therapeutics
Inhibition (Psychology)

Keywords

  • Aromatase inhibitors
  • Gynecomastia
  • Precocious puberty
  • Short stature

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development. / Shulman, Dorothy I.; Francis, Gary L.; Palmert, Mark R.; Eugster, Erica.

In: Pediatrics, Vol. 121, No. 4, 04.2008.

Research output: Contribution to journalArticle

Shulman, Dorothy I. ; Francis, Gary L. ; Palmert, Mark R. ; Eugster, Erica. / Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development. In: Pediatrics. 2008 ; Vol. 121, No. 4.
@article{a193faec45f64eb094cf29a222af7c78,
title = "Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development",
abstract = "Although treatment of children and adolescents who have disorders of growth and adolescent development with aromatase inhibitors is increasingly common, data for or against their use are extremely limited. Precocious puberty, short stature, and gynecomastia are conditions for which inhibition of the enzyme aromatase might prove beneficial to reduce clinical signs of estrogenization and/or estrogen-mediated skeletal maturation. In this report, we summarize the published data regarding the use of aromatase inhibitors in these conditions, and review known and potential benefits, safety concerns, and shortcomings of the available information.",
keywords = "Aromatase inhibitors, Gynecomastia, Precocious puberty, Short stature",
author = "Shulman, {Dorothy I.} and Francis, {Gary L.} and Palmert, {Mark R.} and Erica Eugster",
year = "2008",
month = "4",
doi = "10.1542/peds.2007-2081",
language = "English",
volume = "121",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "4",

}

TY - JOUR

T1 - Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development

AU - Shulman, Dorothy I.

AU - Francis, Gary L.

AU - Palmert, Mark R.

AU - Eugster, Erica

PY - 2008/4

Y1 - 2008/4

N2 - Although treatment of children and adolescents who have disorders of growth and adolescent development with aromatase inhibitors is increasingly common, data for or against their use are extremely limited. Precocious puberty, short stature, and gynecomastia are conditions for which inhibition of the enzyme aromatase might prove beneficial to reduce clinical signs of estrogenization and/or estrogen-mediated skeletal maturation. In this report, we summarize the published data regarding the use of aromatase inhibitors in these conditions, and review known and potential benefits, safety concerns, and shortcomings of the available information.

AB - Although treatment of children and adolescents who have disorders of growth and adolescent development with aromatase inhibitors is increasingly common, data for or against their use are extremely limited. Precocious puberty, short stature, and gynecomastia are conditions for which inhibition of the enzyme aromatase might prove beneficial to reduce clinical signs of estrogenization and/or estrogen-mediated skeletal maturation. In this report, we summarize the published data regarding the use of aromatase inhibitors in these conditions, and review known and potential benefits, safety concerns, and shortcomings of the available information.

KW - Aromatase inhibitors

KW - Gynecomastia

KW - Precocious puberty

KW - Short stature

UR - http://www.scopus.com/inward/record.url?scp=42949151943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42949151943&partnerID=8YFLogxK

U2 - 10.1542/peds.2007-2081

DO - 10.1542/peds.2007-2081

M3 - Article

C2 - 18381525

AN - SCOPUS:42949151943

VL - 121

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 4

ER -